Hematology

Latest News

Cilta-Cel Shows Promising OS Improvement in Lenalidomide-Refractory Multiple Myeloma
Cilta-Cel Shows Promising OS Improvement in Lenalidomide-Refractory Multiple Myeloma

July 17th 2024

Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.

Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL

July 15th 2024

FDA Updates REMS for CAR T-Cell Therapies for Hematologic Malignancies
FDA Updates REMS for CAR T-Cell Therapies for Hematologic Malignancies

July 11th 2024

Prolonging PFS May Be Most Valued Attribute for Patients When Deciding Upon CLL Treatment
Prolonging PFS May Be Most Valued Attribute for Patients When Deciding Upon CLL Treatment

July 9th 2024

Ibrutinib Plus Chemoimmunotherapy Induction Improves Failure-Free Survival in Young Patients With MCL
Ibrutinib Plus Chemoimmunotherapy Induction Improves Failure-Free Survival in Young Patients With MCL

July 6th 2024

Latest CME Events & Activities

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

7th Annual Live Medical Crossfire®: Hematologic Malignancies

View More

Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm

View More

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.